在难治性抑郁症患者中，米氮平与吗氯贝胺联合治疗期间的曲米帕明和马普替林血浆水平。

Trimipramine and maprotiline plasma levels during combined treatment with moclobemide in therapy-resistant depression.

作者信息

König F, Wolfersdorf M, Löble M, Wössner S, Hauger B

机构信息

Department of Psychiatry 1, University of Ulm, Ravensburg, Germany.

出版信息

Pharmacopsychiatry. 1997 Jul;30(4):125-7. doi: 10.1055/s-2007-979497.

DOI:10.1055/s-2007-979497

PMID:9271778

Abstract

In an open pilot study of 21 therapy-resistant depressive inpatients, plasma levels of antidepressants were determined during treatment with a combination of moclobemide/ trimipramine (n = 15) and moclobemide/maprotiline (n = 6). After combined administration of trimipramine and moclobemide (MCB), a significant increase in the plasma level of trimipramine (39%) was observed. After combination of maprotiline with moclobemide, maprotiline levels were increased (25%, n.s.). The results show that moclobemide, as an inhibitor of isoenzymes of the cytochrome P 450 oxidase, can cause increases in the plasma levels of tricyclic and tetracyclic antidepressants. No correlation between the serum level of the antidepressants and treatment outcome was found in this open study.

摘要

在一项针对21名难治性抑郁症住院患者的开放性试验研究中，对接受吗氯贝胺/曲米帕明联合治疗（n = 15）和吗氯贝胺/麦普替林联合治疗（n = 6）的患者测定了血浆中的抗抑郁药水平。联合使用曲米帕明和吗氯贝胺（MCB）后，观察到曲米帕明的血浆水平显著升高（39%）。麦普替林与吗氯贝胺联合使用后，麦普替林水平升高（25%，无统计学意义）。结果表明，作为细胞色素P 450氧化酶同工酶抑制剂的吗氯贝胺可导致三环和四环抗抑郁药的血浆水平升高。在这项开放性研究中，未发现抗抑郁药的血清水平与治疗结果之间存在相关性。